Journal
TRENDS IN IMMUNOLOGY
Volume 30, Issue 8, Pages 392-400Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.it.2009.07.001
Keywords
-
Categories
Funding
- National Institutes of Health [NS-57563, NS-50665]
- National Multiple Sclerosis Society [RG 3892-A-12]
- NIH [T32-NS-48039, T32-AI-07493, F30-NS-65600]
Ask authors/readers for more resources
In the decade following their initial discovery, the suppressor of cytokine signaling (SOCS) proteins have been studied for their potential use as immunomodulators in disease. SOCS proteins, especially SOCS1 and SOCS3, are expressed by immune cells and cells of the central nervous system (CNS) and have the potential to impact immune processes within the CNS, including inflammatory cytokine and chemokine production, activation of microglia, macrophages and astrocytes, immune cell infiltration and autoimmunity. We describe CNS-relevant in vitro and in vivo studies that have examined the function of SOCS1 or SOCS3 under various neuroinflammatory or neuropathological conditions, including exposure of CNS cells to inflammatory cytokines or bacterial infection, demyelinating insults, stroke, spinal cord injury, multiple sclerosis and glioblastoma multiforme.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available